Vertex Pharmaceuticals (VRTX)
(Delayed Data from NSDQ)
$462.88 USD
-0.27 (-0.06%)
Updated Sep 27, 2024 04:00 PM ET
After-Market: $462.85 -0.03 (-0.01%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth D Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$462.88 USD
-0.27 (-0.06%)
Updated Sep 27, 2024 04:00 PM ET
After-Market: $462.85 -0.03 (-0.01%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth D Momentum F VGM
Zacks News
Can Vertex (VRTX) Withstand the Coronavirus Impact on Q1 Earnings?
by Zacks Equity Research
On Vertex's (VRTX) first-quarter earnings call, investor focus will be on the sales uptake of its newly-launched CF drug, Trikafta.
Has Vertex Pharmaceuticals (VRTX) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (VRTX) Outperforming Other Medical Stocks This Year?
Vertex (VRTX) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Vertex (VRTX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Vertex Pharmaceuticals (VRTX) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Vertex (VRTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Scorecard and Top Stock Reports for Alphabet, Gilead & Starbucks
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Alphabet (GOOGL), Gilead Sciences (GILD) and Starbucks (SBUX).
Vertex Pharmaceuticals (VRTX) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Vertex Pharmaceuticals (VRTX) closed at $246.61 in the latest trading session, marking a -1.22% move from the prior day.
The Zacks Analyst Blog Highlights: Amazon, Medtronic, Vertex Pharmaceuticals, Intuit and Bayer
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Amazon, Medtronic, Vertex Pharmaceuticals, Intuit and Bayer
Vertex Pharmaceuticals (VRTX) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $238.31, moving -1.59% from the previous trading session.
Top Research Reports for Amazon, Medtronic & Vertex
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Amazon (AMZN), Medtronic (MDT) and Vertex Pharmaceuticals (VRTX).
3 Drugmakers Still Worth Betting on Amid Coronavirus Woes
by Indrajit Bandyopadhyay
Here we provide three stocks from the drug and biotech sector which can offer protection to an investor's portfolio amid stock market turmoil due to coronavirus crisis.
Is Vertex Pharmaceuticals (VRTX) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (VRTX) Outperforming Other Medical Stocks This Year?
Vertex to Halt Enrollment Due to Coronavirus, Keeps Sales View
by Zacks Equity Research
Vertex (VRTX) announces plan to halt enrollment and delay study initiation amid coronavirus pandemic. However, it does not expect any supply chain disruption and maintains its business outlook for 2020.
Vertex Pharmaceuticals (VRTX) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $213.52, moving +1.46% from the previous trading session.
Zacks.com featured highlights include: Fabrinet, Lumentum, Daqo New Energy and Vertex Pharmaceuticals
by Zacks Equity Research
Zacks.com featured highlights include: Fabrinet, Lumentum, Daqo New Energy and Vertex Pharmaceuticals
The Zacks Analyst Blog Highlights: Regeneron Pharmaceuticals, Co-Diagnostics, Moderna and Vertex Pharmaceuticals
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Regeneron Pharmaceuticals, Co-Diagnostics, Moderna and Vertex Pharmaceuticals
4 Top Biotech Stocks to Buy in the Time of Coronavirus
by Tirthankar Chakraborty
We have picked biotech companies that are widely expected to develop a vaccine for the coronavirus and fight off the worst stock market carnage since the 2008 financial crisis.
Pick These 4 Stocks With Impressive Interest Coverage Ratio
by Sumit Singh
Debt, which is crucial to financing operations for the majority of companies, comes at a cost called interest. Interest expense has a direct bearing on the profitability of a company.
Geron's (GERN) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Geron (GERN) reports encouraging fourth-quarter 2019 results. Operating expenses increase on a year-over-year basis.
BioDelivery (BDSI) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
BioDelivery (BDSI) beats earnings and sales expectations for the fourth quarter of 2019.
Has Vertex Pharmaceuticals (VRTX) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (VRTX) Outperforming Other Medical Stocks This Year?
5 Top Stocks With Great Earnings Beat Potential
by Sanghamitra Saha
These top-ranked stocks are likely to beat on the bottom line in their next release.
Why Is Vertex (VRTX) Down 2.7% Since Last Earnings Report?
by Zacks Equity Research
Vertex (VRTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Perrigo (PRGO) Misses Q4 Earnings Estimates, Tops Revenues
by Zacks Equity Research
Perrigo (PRGO) reports mixed fourth-quarter 2019 results. The addition of products following Ranir acquisition boosts sales in the quarter. Stock declines.
Sarepta (SRPT) Q4 Loss Widens Y/Y, Revenues Miss Estimates
by Zacks Equity Research
Sarepta (SRPT) reports wider year-over-year loss. However, revenues increase year over year.
BioMarin (BMRN) Q4 Earnings Beat, Sales Miss, Valrox in Focus
by Zacks Equity Research
BioMarin (BMRN) announces mixed results for the fourth quarter of 2019, beating estimates for earnings while missing the same for sales.